Neuroepithelial Dysfunction in Chronic Upper Airway Disorders

Abstract

Neuroepithelial dysfunction is increasingly recognized as a central pathophysiological mechanism in a variety of chronic upper airway disorders, including chronic rhinosinusitis, allergic and non-allergic rhinitis, and certain forms of chronic cough. This review synthesizes the current understanding of neuroepithelial alterations, explores their clinical significance, and discusses recent guideline-driven management strategies. By integrating molecular, diagnostic, and therapeutic perspectives, the article aims to provide clinicians and researchers with a comprehensive overview of the implications and emerging directions in the field.

Introduction

Chronic upper airway disorders, such as chronic rhinosinusitis (CRS), allergic rhinitis (AR), and non-allergic rhinitis (NAR), significantly impact patient quality of life and healthcare resources worldwide. Increasing evidence indicates that neuroepithelial dysfunction disruption or maladaptation of the neural and epithelial interface within the respiratory mucosa plays a pivotal role in the onset, persistence, and exacerbation of these conditions. Understanding the mechanisms and clinical implications of neuroepithelial dysfunction is crucial for developing targeted interventions and improving patient outcomes.

Epidemiology / Disease Burden

Chronic upper airway disorders affect approximately 10-15% of the global population, with prevalence rates varying by region and environmental exposures. CRS alone is estimated to impact over 30 million individuals in the United States, while rhinitis (allergic and non-allergic) presents in up to 20% of adults and 40% of children. The burden extends beyond direct symptoms, contributing to sleep disturbance, reduced productivity, and increased healthcare utilization. Neuroepithelial dysfunction is increasingly implicated in refractory cases, influencing both symptom severity and treatment responsiveness.

Pathophysiology

The respiratory epithelium serves as more than a passive barrier; it is a dynamic interface equipped with sensory nerve endings, immune cells, and secretory apparatus. Neuroepithelial dysfunction involves aberrant signaling between epithelial cells and sensory neurons, leading to heightened inflammation, impaired mucociliary clearance, and altered reflex responses (e.g., sneezing, coughing). Key mechanisms include epithelial barrier disruption, increased expression of neuropeptides (such as substance P and calcitonin gene-related peptide), and dysregulation of transient receptor potential (TRP) ion channels. These changes can perpetuate neurogenic inflammation, promote eosinophil and mast cell infiltration, and sustain a cycle of chronic mucosal disease.

Risk Factors

Multiple risk factors contribute to the development of neuroepithelial dysfunction in upper airway disorders. Genetic predisposition, atopy, and environmental exposures (such as pollutants, tobacco smoke, and occupational irritants) are well-established contributors. Recurrent viral or bacterial infections can disrupt epithelial integrity and sensitize neural pathways. Chronic exposure to allergens or irritants may induce epithelial remodeling, heightened neural responsiveness, and persistent neurogenic inflammation. Additionally, underlying comorbidities such as asthma and gastroesophageal reflux disease (GERD) have been linked to increased neuroepithelial vulnerability.

Clinical Features

Neuroepithelial dysfunction manifests clinically as heightened sensory symptoms, including persistent nasal congestion, rhinorrhea, sneezing, itching, and non-productive cough. Patients often report increased sensitivity to environmental triggers (e.g., cold air, odors, or pollutants) and poor response to conventional anti-inflammatory therapies. In CRS, neuroepithelial changes may contribute to olfactory dysfunction, facial pain, and a sensation of nasal obstruction. Objective findings can include swollen mucosa, increased secretions, and mucociliary dysfunction, though these may be non-specific.

Diagnosis

Accurate diagnosis of neuroepithelial dysfunction in chronic upper airway disorders relies on a combination of clinical assessment and objective testing. A detailed history focusing on symptom triggers, duration, and refractoriness to standard treatments is essential. Nasal endoscopy can reveal mucosal edema, polyps, or other structural changes suggestive of chronic inflammation. Recent advances in molecular diagnostics, such as measurement of neuropeptide levels in nasal secretions or epithelial brushings, offer promising tools for identifying neuroepithelial involvement. Patch testing and allergen challenge protocols may help distinguish allergic from non-allergic etiologies.

Treatment & Management

Management strategies for neuroepithelial dysfunction in chronic upper airway disorders are multifaceted. First-line therapy typically includes intranasal corticosteroids to reduce inflammation and promote epithelial healing. Antihistamines and anticholinergic agents target neural pathways to alleviate sensory symptoms. In refractory cases, capsaicin nasal sprays and TRP channel antagonists may modulate neural hyperresponsiveness. Allergen avoidance, environmental control, and treatment of comorbidities (such as asthma or GERD) are critical adjuncts. Patient education and adherence to therapy remain fundamental to achieving symptom control.

Recent Advances / Emerging Therapies

Recent advances focus on targeted modulation of neuroepithelial interactions. Biologic agents directed against key mediators (e.g., anti-IgE, anti-IL-5, and anti-IL-4/13 therapies) show promise in select patient populations, particularly those with eosinophilic inflammation and refractory symptoms. Novel small-molecule inhibitors of TRP channels and neurokinin receptors are under investigation for their ability to reduce neurogenic inflammation and hyperresponsiveness. Advances in epithelial barrier restoration, including agents that enhance tight junction integrity or promote epithelial regeneration, represent emerging therapeutic frontiers. Ongoing research aims to identify biomarkers that accurately reflect neuroepithelial dysfunction and predict treatment response.

Guideline Recommendations

Current clinical guidelines emphasize a stepwise approach to chronic upper airway disorders, with recognition of neuroepithelial dysfunction as a potential contributing factor in refractory or atypical cases. The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) and the American Academy of Otolaryngology–Head and Neck Surgery highlight the importance of comprehensive assessment, including symptom characterization and endoscopic evaluation. For patients with persistent symptoms despite standard therapy, referral to subspecialty care and consideration of advanced diagnostics or biologic therapies are recommended. Multidisciplinary management, particularly in patients with overlapping respiratory or allergic comorbidities, is increasingly advocated.

Conclusion

Neuroepithelial dysfunction represents a critical, yet often under-recognized, mechanism in the pathogenesis and persistence of chronic upper airway disorders. Advances in understanding the molecular and neural interplay underpinning these conditions have opened new avenues for diagnosis and targeted therapy. A nuanced, mechanism-based approach integrating traditional anti-inflammatory modalities with emerging neuro-modulatory strategies holds promise for improved patient outcomes. Ongoing research into biomarker discovery and novel therapeutics will further refine the clinical management of these complex disorders in the years to come.